Therna Biosciences

Executive Summary

Therna Biosciences is a privately held, pre-clinical biotechnology company founded in 2020 and headquartered in Cambridge, Massachusetts. The company is pioneering a novel platform that integrates deep RNA biology with generative artificial intelligence to design programmable RNA therapeutics. Its initial focus is on metabolic and cardiovascular diseases, two large and underserved therapeutic areas with significant unmet medical need. By leveraging AI to rapidly create custom mRNAs and identify optimal targets for silencing oligonucleotides, Therna aims to overcome historical challenges in RNA drug development, such as delivery, stability, and specificity. While still in the pre-clinical stage, the company’s platform has the potential to generate a pipeline of first-in-class or best-in-class candidates. Therna has not yet disclosed its total funding or valuation, indicating it may be operating in relative stealth. The company's success will depend on advancing its lead programs into IND-enabling studies, establishing strategic partnerships, and securing additional financing. If successful, Therna could become a key player in the next wave of RNA therapeutics. However, as a pre-clinical entity with limited public information, the investment risk is high. The conviction score is moderate given the early stage and lack of disclosed data.

Upcoming Catalysts (preview)

• Q1 2027Lead Program IND Filing40% success
• Q3 2026Series A or B Financing Round60% success
• Q4 2026Strategic Partnership or Collaboration50% success